Ruxolitinib Rutinib Cream 1.5% is a specialized prescription topical medication designed to manage inflammatory and pigmentary skin disorders such as atopic dermatitis (eczema) and vitiligo. Its active component, Ruxolitinib, acts as a potent Janus kinase (JAK) inhibitor, which precisely modulates the immune pathway responsible for chronic inflammation and abnormal skin pigmentation. The cream facilitates reduction in skin inflammation and promotes repigmentation by inhibiting the JAK-STAT signaling pathway, which is often upregulated in these conditions. Intended for external use, the cream must be applied strictly as per healthcare provider instructions to maximize therapeutic efficacy while minimizing risks of adverse effects. Produced under stringent GMP and dermatological quality standards, Ruxolitinib Rutinib Cream 1.5% represents a clinically advanced option for managing difficult-to-treat skin diseases with targeted mechanism of action.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Ruxolitinib 1.5% |
| Mechanism of Action | Janus kinase (JAK) enzyme inhibitor |
| Indications | Atopic dermatitis (eczema), Vitiligo |
| Formulation | Topical cream |
| Application | Apply directly to affected skin areas as prescribed |
| Dosage Strength | 1.5% concentration |
| Manufacturing Standards | Produced under rigorous dermatological and GMP quality controls |
| Therapeutic Effects | Reduces inflammation and aids skin repigmentation |
| Prescription Status | Prescription-only medication |
| Safety Measures | Requires adherence to healthcare provider application instructions |
| Attributes | Description |
|---|---|
| Product Type | Topical dermatological cream |
| Active Pharmaceutical Ingredient (API) | Ruxolitinib |
| Concentration | 1.5% w/w |
| Form | Cream |
| Indicated Skin Conditions | Eczema, Vitiligo |
| Application Route | Topical |
| Packaging | Tube or jar (depending on manufacturer) |
| Storage Conditions | Store in a cool, dry place away from direct sunlight |
| Shelf Life | As per manufacturing date (usually 24 months) |
| Regulatory Status | Prescription-only medication requiring healthcare supervision |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
Ruxolitinib Rutinib Cream 1.5% works by inhibiting Janus kinase enzymes that contribute to inflammatory and autoimmune responses involved in the depigmentation process of vitiligo. This aids in promoting repigmentation of the affected skin areas.
Users should apply the cream only on affected areas as prescribed, avoid contact with eyes or mucous membranes, and monitor for any adverse reactions. Consulting a healthcare provider for appropriate usage duration is essential.
Long-term use should be under strict medical supervision as prolonged inhibition of JAK enzymes may affect immune functions. Treatment duration will be determined by the healthcare provider based on clinical response.
Concurrent use with other topical immunosuppressants or corticosteroids should only be done under medical advice to avoid increased side effects or interactions.
The cream is manufactured under stringent GMP and dermatological standards to ensure purity, potency, and safety, aligning with regulatory requirements for prescription dermatological drugs.
Inclusive of all taxes
You Save: 0
Bengaluru , India
Retailer, Brand Owner, Distributor, Exporter, Importer, Wholesaler
GST- 29AQTPJ8785C1Z2
